These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19753618)

  • 1. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
    Phillips KA; Marshall DA; Haas JS; Elkin EB; Liang SY; Hassett MJ; Ferrusi I; Brock JE; Van Bebber SL
    Cancer; 2009 Nov; 115(22):5166-74. PubMed ID: 19753618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer.
    Abratt RP
    S Afr Med J; 2016 Sep; 106(10):981-982. PubMed ID: 27725014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
    Millar JA; Millward MJ
    Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
    McKeage K; Lyseng-Williamson KA
    Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2--a discussion of testing approaches in the USA.
    Thor A
    Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
    Lidgren M; Jönsson B; Rehnberg C; Willking N; Bergh J
    Ann Oncol; 2008 Mar; 19(3):487-95. PubMed ID: 18065409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
    Lidgren M; Wilking N; Jönsson B; Rehnberg C
    Acta Oncol; 2008; 47(6):1018-28. PubMed ID: 18607881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
    Lee JA; Shaheen M; Walke T; Daly M
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
    O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
    Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
    Poncet B; Bachelot T; Colin C; Orfeuvre H; Ganne C; Péaud PY; Jacquin JP; Salles B; Tigaud JD; Méchin-Crétinon I; Maréchal F; Trillet-Lenoir V
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):162-3. PubMed ID: 17357239
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.
    Simoens S
    Pharmacoeconomics; 2007; 25(3):181-5. PubMed ID: 17335304
    [No Abstract]   [Full Text] [Related]  

  • 17. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
    Blank PR; Schwenkglenks M; Moch H; Szucs TD
    Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.
    Barron JJ; Cziraky MJ; Weisman T; Hicks DG
    Oncologist; 2009 Aug; 14(8):760-8. PubMed ID: 19684074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
    Chen W; Jiang Z; Shao Z; Sun Q; Shen K
    Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.